BioAtla (BCAB) Competitors $0.53 -0.03 (-5.36%) As of 01/10/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BCAB vs. ANRO, EDIT, ENTA, VOR, NVCT, TNYA, IVA, MIST, CRDL, and ABOSShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Alto Neuroscience (ANRO), Editas Medicine (EDIT), Enanta Pharmaceuticals (ENTA), Vor Biopharma (VOR), Nuvectis Pharma (NVCT), Tenaya Therapeutics (TNYA), Inventiva (IVA), Milestone Pharmaceuticals (MIST), Cardiol Therapeutics (CRDL), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Alto Neuroscience Editas Medicine Enanta Pharmaceuticals Vor Biopharma Nuvectis Pharma Tenaya Therapeutics Inventiva Milestone Pharmaceuticals Cardiol Therapeutics Acumen Pharmaceuticals Alto Neuroscience (NYSE:ANRO) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk. Is ANRO or BCAB more profitable? Alto Neuroscience's return on equity of -49.28% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -49.28% -33.52% BioAtla N/A -187.30%-96.33% Does the media refer more to ANRO or BCAB? In the previous week, BioAtla had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 3 mentions for BioAtla and 2 mentions for Alto Neuroscience. BioAtla's average media sentiment score of 1.88 beat Alto Neuroscience's score of 0.37 indicating that BioAtla is being referred to more favorably in the news media. Company Overall Sentiment Alto Neuroscience Neutral BioAtla Very Positive Which has better earnings and valuation, ANRO or BCAB? Alto Neuroscience has higher earnings, but lower revenue than BioAtla. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto Neuroscience$210K563.80-$36.31MN/AN/ABioAtla$11M2.33-$123.46M-$1.70-0.31 Does the MarketBeat Community believe in ANRO or BCAB? BioAtla received 11 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 82.35% of users gave Alto Neuroscience an outperform vote while only 67.57% of users gave BioAtla an outperform vote. CompanyUnderperformOutperformAlto NeuroscienceOutperform Votes1482.35% Underperform Votes317.65%BioAtlaOutperform Votes2567.57% Underperform Votes1232.43% Do analysts rate ANRO or BCAB? Alto Neuroscience currently has a consensus price target of $20.00, suggesting a potential upside of 355.58%. BioAtla has a consensus price target of $6.00, suggesting a potential upside of 1,032.08%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.63BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals have more ownership in ANRO or BCAB? 77.2% of BioAtla shares are held by institutional investors. 11.5% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryAlto Neuroscience and BioAtla tied by winning 7 of the 14 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.62M$2.96B$5.27B$8.85BDividend YieldN/A1.94%5.07%4.00%P/E Ratio-0.3146.6186.6616.81Price / Sales2.33414.221,104.19118.42Price / CashN/A182.3143.2437.77Price / Book0.366.315.104.93Net Income-$123.46M-$41.49M$122.02M$227.55M7 Day Performance-11.90%-6.43%-3.41%-4.04%1 Month Performance-63.45%-2.53%0.47%0.77%1 Year Performance-78.01%-1.86%24.97%14.84% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla3.0369 of 5 stars$0.53-5.4%$6.00+1,032.1%-78.0%$25.62M$11M-0.3160Positive NewsANROAlto Neuroscience3.1394 of 5 stars$4.42-4.1%$20.00+352.5%N/A$119.21M$210,000.000.00N/AEDITEditas Medicine4.3506 of 5 stars$1.44+7.5%$7.00+386.1%-86.1%$118.87M$61.76M-0.56230ENTAEnanta Pharmaceuticals4.3281 of 5 stars$5.59+0.2%$17.25+208.6%-54.6%$118.47M$67.64M-1.02145Positive NewsGap DownVORVor Biopharma2.6655 of 5 stars$1.72+30.2%$11.36+560.6%-36.8%$118.06MN/A-1.04140Gap UpNVCTNuvectis Pharma3.1372 of 5 stars$6.03+8.1%$21.00+248.3%-31.1%$116.51MN/A-5.208Gap UpTNYATenaya Therapeutics4.176 of 5 stars$1.47-3.6%$17.33+1,083.2%-52.3%$116.06MN/A-1.02110IVAInventiva3.0333 of 5 stars$2.21+2.3%$13.25+499.5%-51.0%$115.97M$15.62M0.00100Gap UpMISTMilestone Pharmaceuticals2.4613 of 5 stars$2.17-1.4%$13.00+499.1%+34.2%$115.72M$1M-2.6830Gap UpCRDLCardiol Therapeutics2.3954 of 5 stars$1.40-3.1%$8.75+527.2%+23.1%$113.98M$60,000.00-3.5820Positive NewsGap UpABOSAcumen Pharmaceuticals2.9286 of 5 stars$1.88-1.3%$9.33+397.8%-57.5%$112.65MN/A-1.3651Gap Up Related Companies and Tools Related Companies ANRO Alternatives EDIT Alternatives ENTA Alternatives VOR Alternatives NVCT Alternatives TNYA Alternatives IVA Alternatives MIST Alternatives CRDL Alternatives ABOS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCAB) was last updated on 1/13/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
